Oric Pharmaceuticals Stock Investor Sentiment

ORIC Stock  USD 9.80  0.07  0.71%   
About 67% of Oric Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Oric Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Oric Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Oric Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  

Oric Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Oric Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over two months ago at seekingalpha.com         
Stifel starts ORIC at buy, cites prostate cancer drug candidate
seekingalpha News
over two months ago at finance.yahoo.com         
ORIC Pharmaceuticals Reports Inducement Grantsunder Nasdaq Listing Rule 5635
Yahoo News
over two months ago at globenewswire.com         
ORIC Pharmaceuticals Reports Inducement Grantsunder Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over two months ago at globenewswire.com         
Acquisition by Chacko Jacob of 280000 shares of Oric Pharmaceuticals at 4.36 subject to Rule 16b-3
Macroaxis News: globenewswire.com
over two months ago at news.google.com         
Stifel starts ORIC Pharmaceuticals with a buy, 20 target - Investing.com
Google News at Macroaxis
over three months ago at news.google.com         
Technical Data - Stock Traders Daily
Google News at Macroaxis
over three months ago at simplywall.st         
Heres Why Were Not Too Worried About ORIC Pharmaceuticals Cash Burn Situation
Simply Wall St News at Macroaxis
over three months ago at news.google.com         
ORIC Pharmaceuticals Book Value per Share 4.15 - GuruFocus.com
Google News at Macroaxis
over three months ago at news.google.com         
ORIC Pharmaceuticals Long-Term Debt Capital Lea - GuruFocus.com
Google News at Macroaxis
over three months ago at news.google.com         
When the Price of Talks, People Listen - Stock Traders Daily
Google News at Macroaxis
over three months ago at investorplace.com         
ORIC Stock Earnings ORIC Pharmaceuticals Misses EPS for Q2 2024
sbwire news
over three months ago at globenewswire.com         
ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
Macroaxis News: globenewswire.com
over three months ago at benzinga.com         
ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice Presid...
benzinga news
over three months ago at globenewswire.com         
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635
Macroaxis News: globenewswire.com
over three months ago at benzinga.com         
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635
benzinga news
Far too much social signal, news, headlines, and media speculation about Oric Pharmaceuticals that are available to investors today. That information is available publicly through Oric media outlets and privately through word of mouth or via Oric internal channels. However, regardless of the origin, that massive amount of Oric data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Oric Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Oric Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Oric Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Oric Pharmaceuticals alpha.

Oric Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Richard Heyman of 53700 shares of Oric Pharmaceuticals subject to Rule 16b-3
09/06/2024
2
OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration
09/17/2024
3
Disposition of 2089 shares by Multani Pratik S of Oric Pharmaceuticals at 3.25 subject to Rule 16b-3
09/19/2024
4
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635
10/04/2024
5
ORIC Pharmaceuticals Trading Up 4.5 percent Heres Why
10/14/2024
6
Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to its Board of Directors
10/16/2024
7
Acquisition by Chacko Jacob of 510000 shares of Oric Pharmaceuticals at 9.14 subject to Rule 16b-3
11/01/2024
8
ORIC - Oric Pharmaceuticals, Inc. Latest Stock News Market Updates - StockTitan
11/06/2024
9
ORIC Pharmaceuticals Outperform Rating Reaffirmed at Wedbush
11/13/2024
10
ORIC Pharmaceuticals to Participate in Upcoming Investor Confer
11/25/2024

Complementary Tools for Oric Stock analysis

When running Oric Pharmaceuticals' price analysis, check to measure Oric Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oric Pharmaceuticals is operating at the current time. Most of Oric Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oric Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oric Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oric Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
CEOs Directory
Screen CEOs from public companies around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account